Felix Kliewe

An inducible co-stimulator ligand (ICOSL)-based peptide therapy for proteinuric kidney diseases targeting αvβ3 integrin

Abstract Dysregulated αvβ3 integrin activation in podocytes contributes to proteinuric kidney disease by disrupting podocyte architecture and the glomerular filtration barrier. However, no treatments currently exist that therapeutically target this integrin. We previously identif...